B
Brock A. Peters
Researcher at Genentech
Publications - 73
Citations - 7350
Brock A. Peters is an academic researcher from Genentech. The author has contributed to research in topics: Genome & Genomics. The author has an hindex of 27, co-authored 69 publications receiving 6699 citations. Previous affiliations of Brock A. Peters include Johns Hopkins University & University of Liverpool.
Papers
More filters
Journal ArticleDOI
Human Genome Sequencing Using Unchained Base Reads on Self-Assembling DNA Nanoarrays
Radoje Drmanac,Andrew B. Sparks,Matthew J. Callow,Aaron L. Halpern,Norman L. Burns,Bahram G. Kermani,Paolo Carnevali,Igor Nazarenko,Geoffrey B. Nilsen,George Yeung,Fredrik A. Dahl,Andres Fernandez,Bryan Staker,Krishna Pant,Jonathan Baccash,Adam P. Borcherding,Anushka Brownley,Ryan J. Cedeno,Linsu Chen,Daniel F. Chernikoff,Alex Cheung,Razvan Chirita,Benjamin Curson,Jessica Ebert,Coleen R. Hacker,Robert Hartlage,Brian Hauser,Steve Huang,Yuan Jiang,Vitali Karpinchyk,Mark Koenig,Calvin Kong,Tom Landers,Catherine Le,Jia Liu,Celeste E. McBride,Matt Morenzoni,Robert E. Morey,Karl Mutch,Helena Perazich,Kimberly Perry,Brock A. Peters,Joe Peterson,Charit L. Pethiyagoda,Kaliprasad Pothuraju,Claudia Richter,Abraham M. Rosenbaum,Shaunak Roy,Jay Shafto,Uladzislau Sharanhovich,Karen W. Shannon,Conrad G. Sheppy,Michel Sun,Joseph V. Thakuria,Anne Tran,Dylan Vu,Alexander Wait Zaranek,Xiaodi Wu,Snezana Drmanac,Arnold R. Oliphant,William C. Banyai,Bruce L. Martin,Dennis G. Ballinger,George M. Church,Clifford Reid +64 more
TL;DR: A genome sequencing platform that achieves efficient imaging and low reagent consumption with combinatorial probe anchor ligation chemistry to independently assay each base from patterned nanoarrays of self-assembling DNA nanoballs is described.
Journal ArticleDOI
Diverse somatic mutation patterns and pathway alterations in human cancers
Zhengyan Kan,Bijay S. Jaiswal,Jeremy Stinson,Vasantharajan Janakiraman,Deepali Bhatt,Howard M. Stern,Peng Yue,Peter M. Haverty,Richard Bourgon,Jianbiao Zheng,Martin Moorhead,Subhra Chaudhuri,Lynn P. Tomsho,Brock A. Peters,Kanan Pujara,Shaun Cordes,David Davis,Victoria Carlton,Wenlin Yuan,Li Li,Weiru Wang,Charles Eigenbrot,Joshua S. Kaminker,David A. Eberhard,Paul Waring,Stephan C. Schuster,Zora Modrusan,Zemin Zhang,David Stokoe,Frederic J. de Sauvage,Malek Faham,Somasekar Seshagiri +31 more
TL;DR: This study provides an overview of the mutational spectra across major human cancers and identifies several potential therapeutic targets.
Journal ArticleDOI
The PIK3CA gene is mutated with high frequency in human breast cancers
Kurtis E. Bachman,Pedram Argani,Yardena Samuels,Natalie Silliman,Janine Ptak,Steve Szabo,Hiroyuki Konishi,Bedri Karakas,Brian G. Blair,Clarence Lin,Brock A. Peters,Victor E. Velculescu,Ben Ho Park +12 more
TL;DR: It is shown that thirteen of fifty-three breast cancers contain somatic mutations in PIK3CA, with the majority of mutations located in the kinase domain, demonstrating that Pik3CA is the most mutated oncogene in breast cancer.
Journal ArticleDOI
Mutational analysis of the tyrosine phosphatome in colorectal cancers.
Zhenghe Wang,Dong Shen,D. Williams Parsons,Alberto Bardelli,Jason Sager,Steve Szabo,Janine Ptak,Natalie Silliman,Brock A. Peters,Michiel S. van der Heijden,Giovanni Parmigiani,Hai Yan,Tian Li Wang,Greg Riggins,Steven M. Powell,James K V Willson,Sanford D. Markowitz,Kenneth W. Kinzler,Bert Vogelstein,Victor E. Velculescu +19 more
TL;DR: Observations suggest that the mutated tyrosine phosphatases are tumor suppressor genes, regulating cellular pathways that may be amenable to therapeutic intervention.
Journal ArticleDOI
Contribution of bone marrow-derived endothelial cells to human tumor vasculature
Brock A. Peters,Luis A. Diaz,Kornelia Polyak,Leslie Meszler,Kathy Romans,Eva C. Guinan,Joseph H. Antin,David Myerson,Stanley R. Hamilton,Bert Vogelstein,Kenneth W. Kinzler,Christoph Lengauer +11 more
TL;DR: Substantial differences between human tumors and many mouse models with respect to angiogenesis are illustrated and have important implications for the translation of experimental antiangiogenic therapies to the clinic.